跳至主要内容
临床试验/NCT00803907
NCT00803907Unknown4 期

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

University of Sao Paulo1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2008年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
20
试验地点
1
主要终点
post-treatment biopsy

研究概览

简要总结

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

详细描述

This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma).
  • Patients with clinical counter indication for reconstructive surgery (high surgical risk).
  • Patients who have refused a restorative surgery. (aesthetic reasons)
  • Patients who have signed the free and informed consent.

排除标准

  • Patients who have a hypersensitivity reaction to the formula components.
  • Children under 12 years of age.
  • Pregnant and breastfeeding women.
  • Patients whose injury was not confirmed by anatomical and pathological study.
  • Individuals with previous autoimmune or inflammatory disease.
  • Patients who have refused to sign the free and informed term of consent.

研究组 & 干预措施

nodular BCC of the eyelid

Experimental

Patients with nodular BCC of the eyelid

干预措施: Imiquimod 5% cream (Drug)

结局指标

主要结局

post-treatment biopsy

时间窗: post-treatment biopsy

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Erick Marcet Santiago de Macedo

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

University of Sao Paulo

研究点 (1)

Loading locations...

相似试验